New horizons in early stage COPD – Improving knowledge, detection and treatment  by Decramer, Marc et al.
Respiratory Medicine (2011) 105, 1576e1587ava i lab le at www.sc iencedi rect .com
journal homepage : www.e lsev ie r . com/ loca te / rmedREVIEW
New horizons in early stage COPD e Improving
knowledge, detection and treatmentMarc Decramer a, Marc Miravitlles b,*, David Price c,
Miguel Roma´n-Rodrı´guez d, Carl Llor e, Tobias Welte f,
Roland Buhl g, Daniel Dusser h, Katerina Samara i, Nikolaus Siafakas iaRespiratory Division, University of Leuven, Herestraat 49, Leuven, Belgium
b Fundacio Clı´nic, Institut d’Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hospital Clı´nic, CIBER de
Enfermedades Respiratorias (CIBERES), Barcelona, Spain
cCentre of Academic Primary Care, University of Aberdeen, Foresterhill Health Centre, Westburn Road, Aberdeen, UK
d Son Pisa Health Centre for the IB-Salut (Balearic Goverment), Palma de Mallorca (Baleares), Spain
e Primary Healthcare Centre Jaume I, University Rovira i Virgili, Tarragona, Spain
fDepartment of Respiratory Medicine, Medizinische Hochschule Hannover, Germany
g Pulmonary Department, Mainz University Hospital, Germany
hUniversite´ Paris Descarte, Ho¨pital Cochin, APHP, Paris, France
iUniversity General Hospital, Dept. of Thoracic Medicine, Heraklion, Greece
Received 24 September 2010; accepted 20 December 2010
Available online 15 January 2011KEYWORDS
COPD;
Early disease;
Treatment;
Diagnosis;
Case-finding* Corresponding author. Servei de P
E-mail address: Marcm@separ.es (
0954-6111/$ - see front matter ª 201
doi:10.1016/j.rmed.2010.12.015Summary
Early stage COPD carries a significant healthcare burden that is currently underrecognised,
underdiagnosed and undertreated. Furthermore, patients at this stage can rapidly decline to
advanced disease, especially if they continue to smoke. The natural history of the disease in
early stages remains largely unknown, and emerging evidence indicates that we are able to
reduce lung function decline and exacerbations, and improve quality of life, in early stage
COPD, mainly through smoking cessation. But new evidence from randomised clinical trials also
suggests an impact of pharmacotherapy on clinical outcomes in early disease. Guidelines need
to be updated to reflect this greater understanding of early stage disease, and trials need to be
conducted to definitively show the benefits of intensive treatment so that we can meet the
large, unmet clinical needs of this important patient group.
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Chronic obstructive pulmonary disease (COPD) is one of the
main causes of morbidity and mortality in developed
countries.1 The prevalence of spirometrically-confirmed
COPD in England was estimated in 2005 at 1.4%, compared
with 3.6% for coronary heart disease, 1.5% for stroke, 3.3%
for diabetes, 0.5% for cancer, and 5.8% for asthma.2 The
BOLD study, performed in 12 countries using post-bron-
chodilator spirometry testing plus questionnaires on respi-
ratory symptoms, health status, and exposure to COPD risk
factors, revealed that the prevalence of Global Initiative
for Chronic Obstructive Lung Disease (GOLD) stage II or
higher COPD was 10.1% overall, 11.8% in men and 8.5% in
women.3 The overall pooled estimate of the adjusted odds
ratio for COPD was 1.94 per 10-year age increment.3
Early stage chronic obstructive pulmonary disease is
mild or moderate in terms of severity of lung function
impairment and is defined differently depending on which
classification system is used (see Table 1).4e6 However, mild
COPD is consistently defined as a forced expiratory volume
in 1 s (FEV1) of 80% and moderate between 51% and 80%
predicted.4e6 The prevalence of early COPD among patients
with COPD is high and varies significantly between coun-
tries.3 In the BOLD study, the prevalence of GOLD stage I
COPD ranged from 1% in the Philippines to 16% in Austria,e 1 Definitions of mild-to-moderate COPD in current classi
GOLD ATS/ERS
sk  FEV1/FVC >0.70
 FEV1 80%
predicted
Stage I:
 FEV1/FVC <0.70
 FEV1 80%
predicted
 FEV1/FVC 0.70
 FEV1 80%
predicted
erate Stage II:
 FEV1/FVC <0.70
 50%  FEV1 <80%
predicted
 FEV1/FVC 0.70
 FEV1 50e80%
predicted
: forced expiratory volume in 1 s; FVC: forced vital capacity; GOLD
rican Thoracic Society/European Respiratory Society; ICSI: Instituwhile that of GOLD stage II COPD ranged from 5% in
Germany to 12% in South Africa.3 Other local studies have
estimated that, related to spirometry confirmed cases of
COPD, 57% of COPD patients have mild and 25% moderate
disease in Greece,7 compared with 42% and 44%, respec-
tively, in England,8 56% and 38%, in Spain,9 25% and 59%, in
Norway,10 56% and 38%, in Japan,11 and 31% and 51%, in
Poland.12 However, most patients with early disease remain
undiagnosed in the community. A Spanish study in 1999 of
adults aged 40e70 years revealed that, from a prevalence
of 9.1%, only 22% of COPD patients had a previous diagnosis
of the disease,13 which rose to just 27% 10 years later.9
These findings have been replicated around the
globe.7,8,10,11,14 Overall, 45e85% of COPD patients are not
formally diagnosed, as many accept breathlessness and
limited exercise tolerance as features of ageing and regard
their smoker’s cough as normal and do not request medical
attention.15
Both patients and physicians play a role in the high rates
of COPD underdiagnosis. One survey showed that, of 7000
adult respondents, 33% said that they suffered from chronic
respiratory symptoms, but only 56% of those consulted
a physician.16 Of those individuals who consulted a physi-
cian with respiratory symptoms, only 42.6% underwent
spirometry.16 Just 56% of primary care practices were found
to have a spirometer in a recent nationwide survey offication systems.4,6
NICE ICSI
 FEV1/FVC 0.70
 FEV1 80%
predicted
 FEV1 80% predicted
 No abnormal signs
 Cough (sputum)
 Little or no dyspnea
 FEV1/FVC 0.70
 FEV1 50e80%
predicted
 FEV1 50e79% predicted
 Breathlessness (wheeze on
moderate exertion)
 Cough (sputum)
 Variable abnormal signs (general
reduction in breath sounds,
presence of wheezes)
 Hypoxaemia may be present
: Global Initiative for Chronic Obstructive Lung Disease; ATS/ERS:
te for Clinical Systems Improvement.
1578 M. Decramer et al.Spain.17 Lack of time was cited as a reason for not per-
forming spirometry in 20% of cases.17
Undiagnosed airflow obstruction is more common than
doctor-diagnosed COPD and asthma, with a US study esti-
mating the prevalence of undiagnosed airflow obstruction at
12.0% compared with 3.1% and 2.7% for COPD and asthma,
respectively,18 and, although the undiagnosed airflow is
typically very mild, approximately 5% of the general pop-
ulation has an FEV1<75% predicted. Not all patientswithmild
airflow obstruction will progress to more severe disease.19
Yet, despite having milder airflow obstruction than previ-
ously diagnosed patients in the same age group, undiagnosed
patients have significant impairments in health-related
quality of life (HRQoL) and reduced activities of daily living
(ADL) comparedwith individualswithout airflowobstruction.9
As both HRQoL and level of physical activity are important
predictors of survival in patients with COPD,20,21 these results
suggest that, at least in some cases, undiagnosed patients
represent earlier disease than diagnosed individuals and
highlight the importance of early recognition of the disease in
order to implement early intervention, mainly with smoking
cessation initiatives.18 COPD patients also have significantly
lower physical activity than patients with rheumatoid
arthritis and diabetes, and healthy individuals.22
Symptomatic GOLD Stage I COPD patients have increased
respiratory care utilisation, including inhaler use, emergency
room visits, hospitalisation due to respiratory problems and
ambulatory visits, and lower HRQoL than asymptomatic GOLD
Stage I patients. These latter are similar to individuals with
normal lung function.23 Even symptomaticmild COPDpatients
with relativelypreservedFEV1, forcedvital capacity (FVC) and
resting inspiratory capacity have extensive small airway
dysfunction that results in troublesome exertional symp-
toms.24 Regarding extrapulmonary involvement, GOLD Stage I
and II patientsalsohaveanapproximately3-fold increasedrisk
of depressive symptoms compared to healthy individuals.25
The direct health costs of COPD are substantial, even in
early disease. A Spanish 1-year follow-up study estimatedFigure 1 Screening strategies for COPD. Adapted from.30,31 Two
in primary care. In option 1, individuals may be selected for diagn
spirometry in practices in which it is available. Otherwise (option
COPD: chronic obstructive pulmonary disease; IPCRG: Internationa
chronic Obstructive Lung Disease; FEV1: forced expiratory volume
capacity. *See Price et al. (2006), Table 2; **Patients aged 30 years
environmental risk, smoker since childhood).that mild COPD incurred a cost of US$1484 per patient
(versus US$2911 for severe COPD), with hospitalisations
accounting for 41.2%, drug acquisition accounting for 42.5%
and clinic visits and laboratory/diagnostic accounting for
16.2% of the costs.26 In an Italian study, the mean annual
direct healthcare cost per patient was approximately €755
for GOLD Stage 0, €1000 for GOLD Stage I and €2000 for
GOLD Stage III COPD.27 It is likely that these may underes-
timate the true costs of COPD, as COPD is frequently not
listed as the primary reason for hospitalisation.28
The high prevalence and important social and economic
impact of COPD justifies early detection and treatment to
prevent the development of severe stages of the disease. In
this position paper, we will review strategies to detect early
COPD in the community and results reported in large clinical
trials in patientswith stage II COPD,with particular attention
to the possible role of pharmacotherapy in modifying the
course of the disease.Identifying early COPD
While there is a need to improve the recognition of COPD
within the community in a cost-effective and efficient
manner, there is also a need to ensure that, in addressing any
COPDunderdiagnosis, theburdenofCOPDmisdiagnosisdboth
false positives and false negativesdis not increased. Also of
concern is the number of individuals currently diagnosed with
‘COPD’ and/or receiving pulmonary medication who do not
have a clear or accurate diagnosis of COPD in accordancewith
guideline standards.4,29
The International Primary Care Respiratory Group (IPCRG)
suggests that all smokers aged 35 years and older, individuals
who have symptoms suggestive of COPD and those who have
positive findings on a COPD risk evaluation questionnaire
should either have initial case-identification spirometry or
proceed directly to full diagnostic spirometry.30 This ‘case-
finding’ approach of first harnessing symptoms, patientdifferent approaches to identification of individuals with COPD
ostic spirometry based on the results of the case-identification
2), the candidates must be referred for diagnostic spirometry.
l Primary Care Respiratory Group; GOLD: Global initiative for
in 1 s. FEV6: forced expiratory volume in 6 s. FVC: forced vital
or older if high risk (eg, family history of COPD, occupational or
Table 2 Case detection questionnaires.33e35
Authors Questions
van Schayck et al. (2002) 1. How many cigarettes do you smoke each day?
2. Do you have any allergies?
3. Have you ever had asthma or bronchitis?
4. Have you started to get tired more quickly in the past few years?
5. Have you been short of breath more often in the past few years?
6. Have you coughed more in the past few years?
7. Have you started to wheeze in the past few years?
8. Are their any lung diseases in your family?
Martinez et al. (2008) 1. During the past 4 weeks, how much of the time do you feel short of breath?
2. Do you ever cough up any ‘stuff’, such as mucus or phlegm?
3. Please select the answer that best describes you in the past 12 months.
I do less than I used to because of my breathing problems
(strongly agree/agree/unsure/disagree/strongly disagree)
4. Have you smoked at least 100 cigarettes in your entire life?
5. How old are you?
Price et al. (2006) 1. Age group (year)
2. Body mass index (tertiles)
3. Smoking intensity (pack years)
4. Does the weather affect your cough?
5. Do you ever cough up phlegm (sputum) from your chest
when you don’t have a cold?
6. Do you usually cough up phlegm (sputum) from your chest
first thing in the morning?
7. How frequently do you wheeze?
8. Do you have or have you had any allergies?
New horizons in early stage COPD 1579characteristics and lung function indicators should improve
the recognition of COPD (see Fig. 1).31
The NICE guideline recommends the identification of
early COPD and that spirometry be performed in subjects
aged over 35 years, current or ex-smokers and those with
chronic respiratory symptoms.32 It also suggests that
spirometry be considered in patients with chronic bron-
chitis, as a significant proportion of these will go on to
develop airflow limitation.32
Three major case detection questionnaires have been
developed: van Schayck et al33; Martinez et al34; and Price et
al (see Table 2).35,36 Taking an estimated prevalence of COPD
of 10% and two arbitrarily selected cut-off points for each of
the questionnaires, the percentage of individuals requiring
subsequent spirometry and the percentage of false negatives
after application are shown in Table 3. Only for the Price et al
questionnaire has there been an attempt at external vali-
dation within a population of 676 symptomatic smokers
recruited fromboth the general population and fromprimary
care practices.37 For the two previously used cut-off pointsTable 3 Percentage of individuals requiring subsequent spirome
questionnaires.33e36
Price
(>16.5)
Price
(>19.5)
Marti
(>4)
% needing spirometry 26 46 60
% false negatives >4 2 <1
PPV 37 30.3 50.3
NPV 89 92.7 91.7
PPV Z Positive predictive values; NPV Z Negative predictive values.and the same estimated prevalence of COPD, the percentage
needing spirometry and the percentage of false negatives in
the original and validation studies are set out as in Table 4.
However, doubts have been raised as to the applicability of
the validation. As well as differences in the proportion of
smokers between the two populations (100% symptomatic
smokers versus 44.5% smokers with and without respiratory
symptoms in the original population), the Kotz et al patient
group was slightly younger than that in the Price et al pop-
ulation, participants were ineligible if they had a prior
respiratory diagnosis, were using antidepressants or had
undergone spirometry in the preceding 12 months, and the
patients were required to have respiratory symptoms.35,37
While spirometry is an essential part of the clinical diag-
nosis of COPD, with diagnostic criteria based on an FEV1/FVC
ratio <0.7 after inhaled bronchodilator administration,4
21%e63% of patients registered as having COPD in both
primary and secondary care do not fulfil the disease criteria,
largely due to a lack of spirometric data.38e41 A survey of
COPD care within UK general practices indicated that 74% oftry and percentage of false negatives with case-finding COPD
nez Martinez
(>5)
van Schayck
(1 symptom)
van Schayck
(3 symptoms)
43 61 13
1.5 >2 >7
56.8 25 25
86.4 93 94
Table 4 Percentage of individuals requiring subsequent spirometry and percentage of false negatives for Price et al and the
Kotz et al validation sample.35e37
Price (>16.5) Price (>19.5) Kotz (>16.5) Kotz (>19.5)
% needing spirometry 26 46 77 48
% false negatives >4 2 1 3.5
Figure 2 Hypothetical study randomising patients to inten-
sive intervention and symptomatic treatment. D Z Difference
between the two treatment groups. The dashed lines and solid
lines represent two possible evolutions after 2 years. Repro-
duced with permission from.58
1580 M. Decramer et al.COPD patients recently discharged from hospital for an
exacerbation had undergone spirometry in primary care, and
just 55% of patients underwent spirometry in hospital.42
Spirometry is feasible in systematic and opportunistic case-
identification programmes targeted at populations at risk of
COPDdue to smoking, and is likely to benefit patients through
earlier interventions.12,43 Screening spirometry performed
at a sufficient level to rule out COPD can form part of
a strategy to reduce the number of individuals needing full
diagnostic spirometry.30 However, its use in a mass pop-
ulation remains controversial.44
Opportunistic primary care case detection has a COPD
detection rate of up to 28% in previously undiagnosed
smokers.33,45 Case identification of COPD in smokers could
also be widened through the participation of healthcare
professionals other than doctors, such as pharmacists.46
It is possible to achieve good quality spirometry in primary
care,47 andat levels similar tothoseachieved in themajorityof
pulmonary function laboratories.31 However, there is marked
variability and inconsistency in the use of spirometry to diag-
nose COPD48,49 and a lack of device calibration and quality
control,38 as well as formal and accurate technical training,50
are frequent in primary care. A recent document proposing
new standards for general practice diagnostic spirometry that
are compliant with ATS/ERS recommendations, and other
similar initiatives, seeks to improve operator skills to achieve
an acceptable technical standard and quality of spirometry in
primary care.51 Furthermore, the aim of case-finding spirom-
etry is not to provideadefinitivediagnosis but to exclude those
with normal lung function and appropriately guide patients
towards further tests. For case identification, it is therefore
acceptable to perform a less specific, but highly sensitive
test.30 This includes small and simple microspirometers
measuring the FEV1/FEV6 ratio, which could be a reliable
surrogate for FVC in the detection of obstruction.52,53 The
IPCRG has suggested thresholds for excluding COPD using such
devices that require study and validation. These are an FEV1/
FVC ratio of >0.8 and a FEV1 >80% predicted.
30
Clinicians, particularly in primary care, should be offered
a rangeof tools for different levels of COPD identification and
diagnosis adapted to their needs and possibilities, including
short questionnaires to identify patients warranting addi-
tional testing,54 case-identification spirometry and full
diagnostic spirometry. Questionnaires should be applied as
widely as possible to individuals visiting primary care nurses
and pharmacies. As clinicians, we have not succeeded in
advocacy to raise awareness on COPD and the importance of
early diagnosis, and shown the need for spirometry as an
everyday part of primary and secondary care practice.
Spirometry should be encouraged during medical school
training; and patients should expect to undergo spirometry
when they visit their doctor, alongside blood pressure and
blood cholesterol levels assessments, as a marker of general
health. It is also crucial that clinicians and researchers workwith industry to develop spirometry machines that offer
better, standardised results and error messages. Current
pulmonary equipment cannot always perform spirometry to
ATS/ERS standards, and too often industry drives the devel-
opment of spirometry equipment, rather than clinicians
themselves.Early treatment of COPD in current guidelines
Over the past decade, five major guidelines have been pub-
lished on the diagnosis andmanagement of COPD.4e6,32,55 The
2009 updated GOLD report states that, alongside active
reduction of risk factors and influenza vaccination, patients
with Stage Imild COPD should receive symptomatic treatment
with short-acting bronchodilators, while those in Stage II
should also have regular treatment with one or more long-
acting bronchodilators, plus rehabilitation.4 These recom-
mendations were supported by the 2009 ICSI guidelines.5
The 2010 update of the NICE guidelines recommends
that COPD patients with an FEV1 >50% predicted and
exacerbations or persistent breathlessness must be offered
long-acting bronchodilators and, in those with persisting
manifestations, combination therapy with either a long-
acting beta-2 agonist plus an inhaled corticosteroid or
a long-acting beta-2 agonist plus a long-acting anti-
muscarinic agent should be recommended.32
The GOLD report emphasises that the underrecognition
and underdiagnosis of COPD can lead to significant
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implementation of treatment, including smoking cessation,
can prevent or delay the course of airflow obstruction or
reduce its expression. Central to that is the identification of
patients at high risk of COPD.4 The American College of
Physicians concludes that there is evidence to support
inhaled treatment in symptomatic patients with an FEV1
<60% predicted and spirometry in symptomatic adults with
an FEV1 >60% predicted for determining when to initiate
therapy.55 This has recently been challenged by the findings
in TORCH and UPLIFT.56,57 Nevertheless, before the early
treatment of all COPD patients can be recommended
unequivocally, a greater understanding of the natural
progression of COPD in the earlier stages is required and,
more importantly, the detrimental effects of delaying
treatment need to be shown. We therefore need to perform
the hypothetical study in Fig. 2.58 In this study, the effects
of early intensive treatment versus symptomatic treatment
solely with short-acting bronchodilators on FEV1 and other
outcomes would be examined in a group of patients iden-
tified with a screening procedure in general practice and
after successful smoking cessation. Showing a difference
after 1e2 years would not irrefutably show that early
treatment is warranted. Intensive treatment would then
need to be administered to the patients originally rando-
mised to the symptomatic treatment group. If their
outcomes increased to the same levels as the group treated
intensively from early on, early treatment would still not be
mandatory. If, however, a difference in outcomes per-
sisted, then early treatment would be a necessity.
Early intervention studies such as this will never be
carried out without political will and enough resources,
especially as treating more patients and treating them
better will be more expensive in the short term. However,
if early treatment is able to stop the progression of the
disease and reduce hospitalisations in the long term, the
overall costs of COPD treatment will be reduced. An in-
depth cost-effective analysis is the missing link in early
COPD intervention and must be the focus of future
studies.Treatment for early COPD
The principle that patients with early COPD could benefit
significantly from intervention (see Table 5) was established
in 1994 by the Lung Health Study,59 in which 5887 patients
with mild-to-moderate airway obstruction (FEV1 50e90%
predicted and FEV1/FVC 70%) who were otherwise healthy
were randomised to an intensive, long-term smoking cessa-
tion program or usual care for 5 years. Those randomised to
the smoking cessation program were also randomised to
ipratropium bromide 18 mg or placebo three times daily;
however, as use of the active bronchodilator was associated
with a small noncumulative benefit that disappeared after
discontinuation,59 that treatment arm was omitted from
further analyses.60 Sustained smoking cessation was associ-
ated with significantly lower declines in FEV1 than continued
smoking, at 31 ml/year and 62 ml/year (p < 0.001), respec-
tively, and a significant difference in change in FEV1 percent
predicted compared with intermittent smoking, at þ1.98%
and 0.74% (p < 0.001), respectively.60The European Respiratory Study on Chronic Obstructive
Pulmonary Disease (EUROSCOP),61 published in 1999,
investigated the benefits of active treatment in patients
with mild-to-moderate COPD. For this study, 1277 individ-
uals with post-bronchodilator FEV1 50e100% predicted and
FEV1/FVC <70% who continued smoking were randomised
to budesonide 400 mg or placebo twice daily. After 3 years,
there was no difference in the rate of decline in FEV1 in
patients treated with budesonide compared with those
receiving placebo. An initial improvement in lung function
was observed in the first 6 months with budesonide, but no
significant change in decline subsequently, at 57 ml/year
with budesonide versus 69 ml/year with placebo
(p Z 0.39), as the study was powered to detect a differ-
ence of only 20 ml/year.61
A randomised, double-blind, parallel-group clinical trial
nested in the Copenhagen City Heart Study indicated that,
in 290 patients with a mean FEV1 86% predicted, budeso-
nide 400 mg bid, compared with placebo, did not have
a significant impact on the rate of decline of FEV1 or the
number of exacerbations.62 In the Lung Health Study II,
which compared triamcinolone acetonide 600 mg or placebo
bid in 1116 patients with mild-to-moderate COPD, active
treatment had, again, a non-significant effect on the rate
of decline in FEV1. Nevertheless, there was a significant
reduction in respiratory symptoms with triamcinolone
acetonide, at 21.1 per 100 person-years versus 28.2 per 100
person-years for placebo (p Z 0.005), and in visits to
a physician due to respiratory illness, at 1.2 per 100 person-
years versus 2.1 per 100 person-years for placebo
(p Z 0.03).63
A post-hoc analysis of the ISOLDE trial of 751 patients
treated with fluticasone proprionate 500 mg or placebo bid
showed that, in 391 patients with an FEV1 50% predicted,
fluticasone propionate had no impact on the number of
exacerbations per patient per year, at 1.47 versus 1.75
(p Z 0.45). However, the proportion of patients with 1
exacerbations/year treated with oral corticosteroids was
reduced significantly with active treatment, at 8% versus
16% for placebo (pZ 0.02).64 In the ISOLDE trial as a whole,
the annual rate of decline in FEV1 was 50 ml/year in the
fluticasone propionate group and 59 ml/year in the placebo
group (p Z 0.16). Again, the study was powered to detect
only a difference of only 20 ml/year.65
For the BRONCUS study, 523 COPD patients were
randomly assigned to N-acetylcysteine (NAC) 600 mg daily
or placebo and followed-up for 3 years. NAC was found to
have, compared with placebo, no significant effects on
either the decline in FEV1 or the decline in vital capacity
(VC) in 389 participants with GOLD Stage II COPD. Mean
decline in FEV1 was 6 ml/year higher with NAC (pZ 0.589)
and 12 ml/year higher in VC (p Z 0.538).66
The MISTRAL study, published in 2006, randomised 1010
COPD patients to tiotropium 18 mg or placebo once daily for
1 year. Among 426 patients with an FEV1 >50% predicted,
tiotropium was associated with a significant reduction in
the number of exacerbations per patient per year, at 1.21
versus 1.97 (p < 0.001), alongside which there was a non-
significant reduction in the number of patients experi-
encing 1 exacerbation in patients with mild COPD.67
TORCH, which compared salmeterol plus fluticasone
versus both single substances and placebo, included 2156
Table 5 Impact of treatment on early COPD in key trials.
Study (year) Duration/
No randomised/
pre-randomisation
run-in
Intervention Agea/% male/FEV1 % pred
a,b Outcomes
Lung Health Study
(1994)59,60
 5 years
 N Z 5887
 No run-in
 SIA
 SIP
 US
 Ratio: 1:1:1
 SIA: 48.4 years;
60.8% male; 75.1% pred
 SIP: 48.6 years;
64.0% male; 75.2% pred
 UC: 48.4 years;
63.8% male; 75.1% pred
 Y FEV1: Q: 31 ml/year; I: 43 ml/year;
S: 62 ml/year (p < 0.001, S versus Q)
 Y FEV1: SIP: 50 ml/year;
UC: 55 ml/year (NS)
 Δ FEV1 % pred (1 year): Q: þ1.98; I: 1.59;
00.74 (p < 0.001, I versus Q)
EUROSCOP (1999)61  3 years
 N Z 1277
 6 months run-in
 Bud 400 mg bid
 Placebo
 Ratio: 1:1
 52.0 years
 73% male
 77% pred
 Δ FEV1 (6 months): bud: þ17 ml;
placebo: 81 ml (p < 0.001)
 Δ FEV1 (9 months): bud: 57 ml;
placebo: 69 ml (p Z 0.39)
CCHS (1999)62  3 years
 N Z 290
 N/Ac
 Bud 800 mg plus
400 mg daily for 6 months,
400 mg bid for 30 months
 Placebo for 36 months
 Ratio: 1:1
 Bud: 59.0 years;
58.8% male; 86.2% pred
 Placebo: 59.1 years;
62.1% male; 86.9% pred
 Y FEV1: bud: 49.6 ml/year;
placebo: 45.1 ml/year (p Z 0.70)
 No. exacerbations: bud: 155; placebo:
161 (NS)
Lung Health Study
II(2000)63
 40 monthsd
 N Z 1116
 3 months
screening
 Tri 1200 mg per daye
 Placebo
 Ratio 1:1
 Tri: 56.2 years;
64.0% male; 68.5% pred
 Placebo: 56.4 years;
62.1% male; 67.2% pred
 Y FEV1: tri: 44.2 ml/year;
placebo: 47.0 ml/year (p Z 0.50)
 Respiratory symptoms:
tri: 21.1 per 100 person-years; placebo:
28.2 per 100 person-years (p Z 0.005)
 Visits to a physician due to respiratory
illness: tri: 1.2 per 100 person-years;
placebo: 2.1 per 100 person/years
(p Z 0.03)
ISOLDE (2003)64  3 years
 N Z 751 (FEV1 50%
pred: 391)
 8 week run-in
 FP 500 mg bid
 Placebo
 Ratio 1:1
FEV1 50% pred:
 FP: 63.0 years;
63% male; 61% pred
 Placebo: 63.0 years;
66% male; 62% pred
 No. exacerbations/patient/year: FP: 1.47;
placebo: 1.75 (p Z 0.45)
 Patients with 1 exacerbation/year
treated with oral corticosteroids: FP: 8%;
placebo 16% (p Z 0.02)
BRONCUS (2005)66  3 years
 N Z 523 (GOLD
Stage II: 389)
 N/A
 NAC 600 mg daily
 Placebo
 Ratio 1:1
 NAC: 62.0 years;
79% male; 57.0% pred
 Placebo: 62.0 years;
82% male; 57.0% pred
GOLD Stage II:
 Δ decline in FEV1 (NAC versus placebo):
6 ml/year (p Z 0.589)
 Δ decline in VC (NAC versus placebo):
12 ml/year (p Z 0.538)
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MISTRAL (2006)67  1 year
 N Z 1010 (FEV1 >50%
pred: 426)
 3 weeks screening
 Tio 18 mg qd
 Placebo
 Ratio: 1:1
 Tio (all patients): 64.5 years;
89.0% male; 48.2% pred
 Placebo (all patients):65.0 years;
87.0% male; 47.6% pred
FEV1 >50% pred:
 No. exacerbations/patient/year: tio: 1.21; placebo:
1.97 (p < 0.01)
Mild COPD:
 Patients with 1 exacerbation: tio: 13.1%;
placebo: 15.6% (NS)
 No. exacerbations/patient/year: tio: 0.47;
placebo: 0.72 (NS)
TORCH (2008)56,68  3 years
 N Z 6112 (GOLD
Stage II: 2156)
 2 weeks run-in
 Sal 50 mg bid
 FP 500 mg bid
 SFC 50 mg/500 mg bid
 Placebo
 Ratio: 1:1:1:1
GOLD Stage II:
 64.9 years
 72.0% male
 58.8% pred
GOLD Stage II:
 [ FEV1 (SFC versus placebo): 101 ml
 Δ decline in FEV1 (SCF versus placebo): 16 ml/year
 No. exacerbations/patient/year: SFC: 0.57; placebo: 0.82
 Δ SGRQ score (SFC versus placebo): 2.3
UPLIFT (2008)57,69  4 years
 N Z 5993 (GOLD
Stage II: 2739)
 14e30 days screening
 Tio 18 mg qd
 Placebo
 Ratio 1:1
GOLD Stage II:
 65.0 years
 72.0% male
 59% pred
GOLD stage II:
 Δ decline in FEV1 (tio versus placebo): 6 ml/year
 No. exacerbations/patient/year: tio: 0.56;
placebo: 0.70 (p < 0.0001)
 Median time to 1st exacerbation: tio: 23.1 months;
placebo: 17.5 months (p < 0.001)
 Δ SGRQ score (tio versus placebo): 2.7 to 4.0
(p  0.00.06 at all time points)
O’Donnell
et al. (2009)71
 28 days
 N Z 16
 N/A
 IB 500 mg
 Placebo
 Ratio 1:1 (crossover)
 63.0 years
 63.0% male
 90% pred
60 min:
 FEV1: IB: 2.46 l; placebo 2.30 l (p < 0.05)
 RV: IB: 2.49 l; placebo: 2.73 l (p < 0.05)
 sRaw: IB: 9.3 cm H20.s; placebo: 12.7 cm H20.s (p < 0.05)
Isotime during constant-load exercise:
 Dyspnoea/minute ventilation: IB: 0.10 Borg/l/min;
placebo 0.12 Borg/l/min (p < 0.05)
 Tidal volume: IB: 1.99 l; placebo: 1.83 l (p < 0.05)
FEV1: forced expiratory volume in 1 s; Pred: predicted; EUROSCOP: European Respiratory Society Study on Chronic Obstructive Pulmonary Disease; Bud: budesonide SIA: intensive long-term
smoking cessation plus ipratropium bromide 18 mg three times daily; SIP intensive long-term smoking cessation plus placebo; US: usual care; Q: sustained quitters; I: intermittent quitters;
S: continuing smokers; Tri: triamcinolone acetonide; ISOLDE: Inhaled Steroids in Obstructive Lung Disease in Europe; Flu: fluticasone propionate; BRONCUS: Bronchitis Randomized on NAC
Cost-Utility Study; GOLD: Global Initiative for Chronic Obstructive Lung Disease; NAC: N-acetylcysteine; VC; vital capacity; MISTRAL: Mesure de l’Influence de Spiriva sur les Troubles
Respiratoires Aigus a` Long terme; Tio: tiotropium; TORCH: Towards a Revolution in COPD Health; UPLIFT: Understanding Potential Long-term Impacts on Function and Tiotropium; Sal:
salmeterol; SFC: salmeterol/fluticaone propionate combined; SGRQ: St George’s Respiratory Questionnaire; IB: ipratropium bromide; RV: respiratory volume; sRaw: specific airway
resistance.
a Mean.
b Postbronchodilator.
c Nested in epidemiological study.
d Mean follow-up.
e Six inhalations bid.
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1584 M. Decramer et al.patients with GOLD stage II disease, who had a mean
baseline FEV1 of 58.8% predicted.
56 Post-hoc analysis
showed that, compared with placebo, salmeterol plus flu-
ticasone was associated with an increase in FEV1 of 101 ml
and a decrease in the decline of FEV1 of 16 ml/year. This
compared with an increase in FEV1 of 46 ml and a decrease
in the decline of FEV1 of 14 ml/year with fluticasone alone,
and with an increase in FEV1 of 67 ml and a decrease in the
decline of FEV1 of 20 ml/year with salmeterol alone.
Furthermore, combination therapy significantly reduced
the number of exacerbations per patient per year
compared with placebo, at 0.57 and 0.82, respectively. This
compared with rates of exacerbations per patient per year
of 0.68 and 0.71 for fluticasone alone and salmeterol alone,
respectively. St George’s Respiratory Questionnaire (SGRQ)
scores were improved with combination therapy by 2.3
compared with placebo, versus 1.4 and 2.2 with flutica-
sone alone and salmeterol alone, respectively.56 Reduction
of exacerbations in this post-hoc analysis was significant,56
and the improvements in lung function and outcomes were
in proportion to those observed in the overall study
population.68
In UPLIFT, which compared tiotropium bromide versus
placebo, 2739 (46%) patients were in GOLD Stage II.57,69 Pre-
specified secondary analysis demonstrated that treatment
with tiotropium in these patients significantly reduced rates
of decline in post-bronchodilator FEV1 compared with
placebo (43  2 ml/year versus 49  2 ml/year;
p Z 0.024), with improvements in lung function sustained
over 4 years. Tiotropium also, compared with placebo,
significantly reduced the number of exacerbations per
patient per year, at 0.56 versus 0.70 (p < 0.0001) and
significantly increased the median time to the first exacer-
bation, at 23.1 months versus 17.5 months (p < 0.001).
Active treatment significantly improved SGRQ scores at all
time points during follow-up, at reductions in scores ranging
from 2.7 to 4.0 (p  0.06 at all time points).57 Importantly,
the benefits of tiotropium observed in the MISTRAL and
UPLIFT studies occurred despite patients being allowed to
receive other drugs, such as ICS (61%e74%, respectively)
and/or LABA (32%e72%, respectively).67,69 Crucially,
a further pre-specified analysis of the UPLIFT data in 810
treatment naı¨ve patients, 60% of whom were in GOLD Stage
II, showed that tiotropium, compared with placebo, was
associated with a significantly lower rate of post-broncho-
dilator decline in FEV1 (42 4ml/year versus 53 4ml/year;
pZ 0.026), a significantly higher morning pre-dose FEV1 at
48 months (134 ml higher for tiotropium; p < 0.001), and
a significantly slower decline in SGRQ total score (difference
1.05  0.34 units/year; pZ 0.002).70
Early treatment may also have an impact on exercise
capacity. A study by O’Donnell et al demonstrated that, in
16 patients with symptomatic GOLD Stage I COPD, neb-
ulised ipratropium bromide 500 mg significantly increased
pulmonary function, as measured by FEV1, residual volume
and specific airway resistance (p < 0.005 for all), within
2 h. Furthermore, during constant-load exercise, active
treatment was associated with a significant reduction in
dyspnoea per minute ventilation and a significant increase
in tidal volume (p < 0.05 for both).71 These trials, overall,
demonstrate that, in the early studies, inhaled cortico-
steriods did not improve lung function and improvementswith salmeterol/fluticasone in the TORCH study were
confined to patients with an FEV1 between 50% and 60%. All
other interventions were associated with negative results,
aside from intensive smoking intervention and use of long-
acting bronchodilators. In terms of future trials, we need to
reconsider the inclusion and exclusion criteria, and multi-
variate regression analysis of variables will indicate
whether treatments are effective. Reversible COPD
patients, who are more prevalent in early stages of COPD,
should not be excluded. It is also important to note that
patients do not complain of FEV1, they complain of symp-
toms and HRQoL, so these need to be included in all
outcomes of trials, and more emphasis needs to be placed
on assessing them. In the future, we need to think about
different ways of preventing HRQoL reductions, as there is
a large, unmet need in terms of impairment. Furthermore,
to show treatment benefits, it is important that investiga-
tors focus on demonstrating real and tangible benefits by
using combined end-points in larger numbers of patients
and ensuring that the studies are sufficiently powered to
reveal clinical and significant differences. Although there is
still room for improvement, trials such as UPLIFT and
TORCH have begun to address these problems.
In summary, early stage COPD is underrecognised and
underdiagnosed, yet has a substantial impact on patients’
lives that is out of proportion to measurable reductions in
lung function. The tools to detect early stage COPD in
primary and secondary care are widely available, and
emerging evidence strongly suggests that we can improve
patients’ lung function and quality of life, as well as reduce
exacerbations, with early, intensive treatment. It is time to
take these important messages to governments, healthcare
providers and patients, and begin the trials that will defini-
tively show the benefits we are already beginning to see.
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